Key Highlights

  • Compass Pathways (NASDAQ:CMPS) shows a 109.03% change in basic EPS with no product revenue, a second-quarter net loss of USD 253.8 million and about USD 433 million of cash at June 30.
  • Kura Oncology (NASDAQ:KURA) posted second-quarter revenue of USD 20.87 million from its Komzifti launch, and its 48.78% EPS rise measures a narrowing loss at roughly 10.6 times annualised sales on simple arithmetic.
  • Capricor Therapeutics (NASDAQ:CAPR) faces an FDA target action date of Sunday, November 22, 2026 for deramiocel, and its 48.91% EPS rise is a narrowing loss at a market value of about USD 384 million.
  • Zymeworks (NASDAQ:ZYME) closed its Theravance Biopharma acquisition on Wednesday, September 23, 2026, adding YUPELRI cash flow, while its 105.54% EPS rise reflects lumpy partner income on a loss-making trailing base.

Compass Pathways (NASDAQ:CMPS): psilocybin therapy nearing a filing

Compass Pathways (NASDAQ:CMPS), which develops COMP360, a synthetic psilocybin therapy, traded near USD 12.00 early in the session of Wednesday, October 21, 2026, at a market value near USD 1.66 billion. Market data put the year-to-date gain near 72.5% at the close of Tuesday, October 20. Phase 3 results in treatment-resistant depression, meaning depression that has not responded to at least two standard treatments, were reported on Tuesday, July 7, 2026, and 52-week open-label data from the COMP005 trial followed on Wednesday, September 9, when the shares rose 8.05%. COMP360 holds Breakthrough Therapy designation from the FDA.

The 109.03% change in basic EPS is a percentage move in a negative figure. The second-quarter net loss of USD 253.8 million was close to the full-year 2025 loss of USD 269.8 million, and the 2025 operating loss was USD 179.0 million, so about USD 90.8 million of the annual loss came from items below operating income, simple arithmetic on reported figures. Such items often include fair-value changes on warrants, which rise with the share price. Approval also requires rescheduling of psilocybin by the Drug Enforcement Administration, an automatic shelf filed on Wednesday, August 5, 2026 allows quick equity sales, and short interest sits near 13.3% of the float.

Kura Oncology (NASDAQ:KURA): a first commercial launch

Kura Oncology (NASDAQ:KURA) sells Komzifti (ziftomenib), a menin inhibitor for a genetically defined form of acute myeloid leukaemia, a blood cancer. The shares traded near USD 10.13 early on Wednesday, October 21, 2026, about 27% below a 52-week high of USD 13.90, for a market value of about USD 884.5 million to USD 899.4 million. Second-quarter revenue was USD 20.87 million against consensus of USD 20.16 million, and the adjusted loss of USD 0.77 per share was narrower than the expected USD 0.88. UBS reiterated a Buy rating and a USD 15.00 target on Monday, October 5, 2026.

Basic EPS remains negative, so the 48.78% improvement reflects a smaller loss rather than profit growth. It has two operating sources: Komzifti product revenue, and collaboration revenue under the partnership with Kyowa Kirin, which shares development and commercial costs. That makes it the most operationally grounded improvement in the group, although one quarter above consensus does not establish a trajectory. The main risks are launch pace in a narrow patient subgroup, competition among menin inhibitors and continued cash use while a 10-year Treasury yield of 5.12% on Tuesday, October 20, 2026 raises the cost of new capital.

Capricor Therapeutics (NASDAQ:CAPR): a binary FDA date

Capricor Therapeutics (NASDAQ:CAPR) develops deramiocel, an investigational cell therapy for Duchenne muscular dystrophy, an inherited disease that progressively destroys muscle in boys. It submitted a major amendment to its Biologics License Application, and the FDA target action date is Sunday, November 22, 2026. On Monday, October 5, 2026, HOPE-3 extension data showed that patients switched from placebo declined by 0.49 points on the PUL 2.0 upper-limb scale in their second year, against 2.05 points in year one, a 76% reduction. The shares fell from USD 7.83 on Friday, October 9 to near USD 6.63 early on Wednesday, October 21, far below a 52-week high of about USD 40.37.

The 48.91% EPS rise is a narrowing loss on a negative base for a company without approved products, so it carries no information on durability. The company states that no statistical alpha, the error budget for formal testing, was allocated to the extension analyses, so the decision rests on how the FDA weighs controlled and open-label evidence. Approval could bring a Priority Review Voucher, a transferable regulatory asset. Litigation with Nippon Shinyaku and NS Pharma over distribution rights, and funding needs at higher capital costs, are the other risks.

Zymeworks (NASDAQ:ZYME): royalties plus an acquired product

Zymeworks (NASDAQ:ZYME) discovered Ziihera (zanidatamab), a HER2-targeted bispecific antibody commercialised by Jazz Pharmaceuticals (NASDAQ:JAZZ) and BeOne Medicines (NASDAQ:ONC). It completed the Theravance Biopharma acquisition on Wednesday, September 23, 2026, in a deal valued at about USD 929 million and financed partly with USD 350 million of senior secured notes. The shares traded near USD 27.25 early on Wednesday, October 21, close to the top of a 52-week range of about USD 16.00 to USD 31.34, for a market value of about USD 1.95 billion. Results are due after the close on Monday, November 9, 2026.

The 105.54% improvement reflects partner milestones and royalties set against research costs on a negative trailing base, so it is a narrowing loss and partly a timing effect of milestones. YUPELRI, an inhaled treatment for chronic obstructive pulmonary disease, adds a recurring revenue stream that could make earnings less lumpy. The new secured notes add interest costs in a period of rising policy rates, so free cash flow, not reported earnings, becomes the cleaner test. Integration of the acquired commercial unit and partner execution are the other risks.

Where Things Stand

The answer is that none of the four EPS figures measures durable profit, because every trailing base is negative and the growth comes from smaller per-share losses, partner income or non-cash items. Value rests on events: Compass Pathways (NASDAQ:CMPS) trades at about 3.8 times its June 30 cash on simple arithmetic, pricing approval odds, while Kura Oncology carries the only product-led improvement and Capricor near USD 6.63 prices a binary FDA risk. Zymeworks near the top of its range already reflects the Theravance shift. Loss-making biotech depends on equity funding, and the Federal Reserve raised its target range to 3.75% to 4.00% on Wednesday, September 16, 2026. The next catalysts are the Fed decision on Wednesday, October 28, results on Tuesday, November 3 and Monday, November 9, the Capricor target date of Sunday, November 22 and the Fed decision on Wednesday, December 9, 2026. Regulatory dates are targets, clinical outcomes are uncertain, and this is not investment advice.